O Grech-Bélanger

554 total citations
26 papers, 463 citations indexed

About

O Grech-Bélanger is a scholar working on Analytical Chemistry, Pharmacology and Pharmacology. According to data from OpenAlex, O Grech-Bélanger has authored 26 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Analytical Chemistry, 9 papers in Pharmacology and 8 papers in Pharmacology. Recurrent topics in O Grech-Bélanger's work include Analytical Methods in Pharmaceuticals (12 papers), Analytical Chemistry and Chromatography (8 papers) and Pharmacogenetics and Drug Metabolism (8 papers). O Grech-Bélanger is often cited by papers focused on Analytical Methods in Pharmaceuticals (12 papers), Analytical Chemistry and Chromatography (8 papers) and Pharmacogenetics and Drug Metabolism (8 papers). O Grech-Bélanger collaborates with scholars based in Canada, United Kingdom and France. O Grech-Bélanger's co-authors include Jacques Turgeon, M. R. Gilbert, P M Bélanger, Andrew C. G. Uprichard, Dean W.G. Harron, Céline Fiset, Klaus Moerike, H. Kroemer, Jacques R. Rouleau and Michel Eichelbaum and has published in prestigious journals such as Analytical Biochemistry, Biochemical and Biophysical Research Communications and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

O Grech-Bélanger

25 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O Grech-Bélanger Canada 13 192 180 136 129 99 26 463
H. Spahn Germany 17 147 0.8× 228 1.3× 144 1.1× 157 1.2× 109 1.1× 52 623
J. X. de Vries Germany 19 226 1.2× 200 1.1× 142 1.0× 105 0.8× 217 2.2× 55 832
K Beschke Germany 9 91 0.5× 148 0.8× 108 0.8× 86 0.7× 92 0.9× 9 423
P M Bélanger Canada 18 359 1.9× 136 0.8× 76 0.6× 140 1.1× 197 2.0× 50 888
E. Moro Italy 15 91 0.5× 92 0.5× 62 0.5× 143 1.1× 126 1.3× 33 549
K J Hoffmann Sweden 14 178 0.9× 84 0.5× 62 0.5× 75 0.6× 61 0.6× 20 367
Edward C. Conradi United States 13 211 1.1× 96 0.5× 180 1.3× 164 1.3× 70 0.7× 19 658
Y. Shiobara United Kingdom 11 93 0.5× 59 0.3× 92 0.7× 102 0.8× 91 0.9× 22 409
D. A. Garteiz United States 11 81 0.4× 122 0.7× 89 0.7× 60 0.5× 99 1.0× 18 377
B. K. MARTIN United Kingdom 15 218 1.1× 92 0.5× 93 0.7× 150 1.2× 184 1.9× 35 673

Countries citing papers authored by O Grech-Bélanger

Since Specialization
Citations

This map shows the geographic impact of O Grech-Bélanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O Grech-Bélanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O Grech-Bélanger more than expected).

Fields of papers citing papers by O Grech-Bélanger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O Grech-Bélanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O Grech-Bélanger. The network helps show where O Grech-Bélanger may publish in the future.

Co-authorship network of co-authors of O Grech-Bélanger

This figure shows the co-authorship network connecting the top 25 collaborators of O Grech-Bélanger. A scholar is included among the top collaborators of O Grech-Bélanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O Grech-Bélanger. O Grech-Bélanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Michaud, Véronique, Samer Mouksassi, Line Labbé, et al.. (2006). Inhibitory Effects of Propafenone on the Pharmacokinetics of Caffeine in Humans. Therapeutic Drug Monitoring. 28(6). 779–783. 6 indexed citations
2.
Turgeon, Jacques, et al.. (1992). Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination.. Drug Metabolism and Disposition. 20(5). 762–769. 22 indexed citations
3.
Grech-Bélanger, O, et al.. (1991). Meta-hydroxymexiletine, a new metabolite of mexiletine. Isolation, characterization, and species differences in its formation.. Drug Metabolism and Disposition. 19(2). 458–461. 10 indexed citations
4.
Turgeon, Jacques, Céline Fiset, Robert Giguère, et al.. (1991). Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.. Journal of Pharmacology and Experimental Therapeutics. 259(2). 789–798. 53 indexed citations
5.
Grech-Bélanger, O, et al.. (1989). Pharmacokinetics of Mexiletine in the Elderly. The Journal of Clinical Pharmacology. 29(4). 311–315. 9 indexed citations
6.
Grech-Bélanger, O, et al.. (1988). Pharmacokinetics of Diltiazem in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. The Journal of Clinical Pharmacology. 28(5). 477–480. 10 indexed citations
7.
Turgeon, Jacques, O Grech-Bélanger, & M. R. Gilbert. (1987). Erythrocyte and serum distribution of mexiletine in man. Biopharmaceutics & Drug Disposition. 8(6). 571–576. 4 indexed citations
8.
Grech-Bélanger, O, et al.. (1987). Deacetylation of diltiazem by rat liver.. Drug Metabolism and Disposition. 15(1). 122–126. 20 indexed citations
9.
Grech-Bélanger, O, et al.. (1987). Assay of diltiazem and deacetyldiltiazem by capillary gas chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 417(1). 89–98. 15 indexed citations
10.
Grech-Bélanger, O, Jacques Turgeon, & M. R. Gilbert. (1986). Stereoselective disposition of mexiletine in man.. British Journal of Clinical Pharmacology. 21(5). 481–487. 61 indexed citations
11.
Grech-Bélanger, O. (1986). Clinical Pharmacokinetics of Mexiletine. 4(6). 553–560.
12.
Grech-Bélanger, O, Jacques Turgeon, & M. R. Gilbert. (1985). High-performance liquid chromatographic assay for mexiletine enantiomers in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 337(1). 172–177. 37 indexed citations
13.
Grech-Bélanger, O, et al.. (1985). Effect of cigarette smoking on mexiletine kinetics. Clinical Pharmacology & Therapeutics. 37(6). 638–643. 47 indexed citations
14.
Grech-Bélanger, O. (1984). Gas chromatographic method for the routine serum monitoring of mexiletine. Journal of Chromatography B Biomedical Sciences and Applications. 309(1). 165–169. 12 indexed citations
15.
Grech-Bélanger, O, et al.. (1983). Inhibitory Effect of Isoniazid on Antipyrine Clearance in Man. The Journal of Clinical Pharmacology. 23(11). 540–544. 2 indexed citations
16.
Bélanger, P M & O Grech-Bélanger. (1982). Gas—liquid chromatographic determination of plasma and urinary levels of amantadine in man. Journal of Chromatography B Biomedical Sciences and Applications. 228. 327–332. 23 indexed citations
17.
Bélanger, P M, et al.. (1981). Colorimetric determination of N-hydroxylated metabolites in microsomal studies. Analytical Biochemistry. 118(1). 47–52. 21 indexed citations
18.
Bélanger, P M, O Grech-Bélanger, & Robert F. Labadie. (1979). Depression of hepatic microsomal enzyme systems by amantadine hydrochloride in the rat.. Journal of Pharmacology and Experimental Therapeutics. 211(3). 485–490. 11 indexed citations
19.
Bélanger, P M & O Grech-Bélanger. (1979). Metabolic reduction of 1-nitrosoadamantane by rabbit liver microsomes. Properties of a C-nitroso reductase system.. Drug Metabolism and Disposition. 7(3). 171–175. 4 indexed citations
20.
Bélanger, P M & O Grech-Bélanger. (1977). The identification of the n oxidized metabolic products of amantadine in the rabbit. 12(4). 99–102. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Spahn Breakdown of academic impact, for papers by J. X. de Vries Breakdown of academic impact, for papers by K Beschke Breakdown of academic impact, for papers by P M Bélanger Breakdown of academic impact, for papers by E. Moro Breakdown of academic impact, for papers by K J Hoffmann Breakdown of academic impact, for papers by Edward C. Conradi Breakdown of academic impact, for papers by Y. Shiobara Breakdown of academic impact, for papers by D. A. Garteiz Breakdown of academic impact, for papers by B. K. MARTIN
Rankless by CCL
2026